Unlock instant, AI-driven research and patent intelligence for your innovation.
C-indican derivative
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound, pharmaceutical technology, applied in the field of medicine, can solve problems such as insufficient net energy
Active Publication Date: 2015-01-14
SHANDONG XUANZHU PHARMA TECH CO LTD
View PDF7 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although this pathway does not directly contribute to the pathophysiology of type 2 diabetes, lowering blood glucose by increasing renal glucose excretion induces a net energy deficit, promotes weight loss and indirectly improves obesity symptoms
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0116] Dissolve raw material 1 and N-methylmorpholine in THF, cool under nitrogen protection, slowly add trimethylsilicon chloride dropwise, keep the temperature, heat up and stir the reaction after completion, then stir the reaction at room temperature, add toluene to dilute and cool down, Water was added to maintain the temperature, and the organic phase of the reaction mixture was separated and washed with aqueous sodium dihydrogen phosphate, water, and saturated brine, respectively. Rotary evaporation afforded a pale yellow oil.
[0167] Dissolve raw material 1 (239g, 1.34mol) and N-methylmorpholine (1.18L, 10.73mol) in THF (2.4L), cool to -5°C under nitrogen protection, and slowly add trimethylsilylchloride dropwise (1022mL, 8.05mol), keep the temperature during the dropwise addition not exceeding 5°C, after completion, raise the temperature to 35°C and stir for 5h, then stir at room temperature for 15h, add toluene to dilute and cool to 0-5°C, then add water to keep the temperature not exceeding 10 °C, the organic phase of the reaction mixture was separated and washed with aqueous sodium dihydrogen phosphate, water and saturated brine, respectively. Rotary evaporation gave 593.2 g of light yellow oil 2,3,4,6-tetrakis(trimethylsilyl ...
Embodiment 2
[0189] Example 2 β-1'-deoxy-1'-(4-chloro-3-(3,3a,4,9,9a-hexahydronaphthalene[2,3-c]furan-6-methylene)benzene )-glucose acetal (compound Preparation of substance 2)
[0190]
[0191] Reference Example 1 to obtain the compound β-1'-deoxy-1'-(4-chloro-3-(3,3a,4,9,9a-hexahydronaphthalene[2,3-c]furan-6-methylene base) phenyl)-glucose acetal. LC-MS(M+H) + :461.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the technical field of medicine, and particularly relates to C-indican derivative as shown in general formula (I), the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The invention specifically relates to the C-indican derivative taken as sodium-dependent glucose transporters (SGLT) inhibitor, the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The C-indican derivative provided by the invention not only can be used for the diabetes mellitus such as the insulin dependent diabetes mellitus (I type diabetes mellitus), the non-insulin dependent diabetes mellitus (II type diabetes mellitus) and the like, but also can be used for the treatment and the prevention of various mellitus-related diseases such as the insulin-resistant disease and the fatness. R1, R2, R3, R4, R5, R6a, R6b, R6c, W, M, n and A are defined in the specification.
Description
1. Technical field [0001] The invention belongs to the technical field of medicine and relates to C-glycoside derivatives, their pharmaceutically acceptable salts, their easily hydrolyzed esters, their stereoisomers and intermediates. It specifically relates to C-glycoside derivatives as sodium-glucose cotransporter (SGLT) inhibitors, their pharmaceutically acceptable salts, their easily hydrolyzed esters, their stereoisomers and intermediates. The C-glycoside derivatives of the present invention can be used not only for diabetes such as insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes), but also for various diseases including insulin resistancedisease and obesity. treatment of diabetes-related diseases, and the prevention of these diseases. 2. Background technology [0002] Approximately 100 million people worldwide suffer from type 2 diabetes, characterized by hyperglycemia due to excess hepatic glucose production and peri...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More